A detailed history of Virtus ETF Advisers LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 1,189 shares of MDGL stock, worth $252,579. This represents 0.17% of its overall portfolio holdings.

Number of Shares
1,189
Previous 368 223.1%
Holding current value
$252,579
Previous $98,000 239.8%
% of portfolio
0.17%
Previous 0.05%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$193.33 - $291.99 $158,723 - $239,723
821 Added 223.1%
1,189 $333,000
Q1 2024

May 15, 2024

SELL
$171.37 - $283.23 $4,969 - $8,213
-29 Reduced 7.3%
368 $98,000
Q4 2023

Feb 15, 2024

BUY
$120.4 - $237.13 $1,083 - $2,134
9 Added 2.32%
397 $91,000
Q3 2023

Nov 07, 2023

SELL
$146.04 - $225.78 $5,257 - $8,128
-36 Reduced 8.49%
388 $56,000
Q2 2023

Aug 14, 2023

SELL
$203.88 - $312.0 $266,878 - $408,408
-1,309 Reduced 75.53%
424 $97,000
Q1 2023

May 15, 2023

SELL
$231.06 - $307.08 $153,885 - $204,515
-666 Reduced 27.76%
1,733 $419,000
Q4 2022

Feb 14, 2023

BUY
$58.39 - $296.54 $51,383 - $260,955
880 Added 57.93%
2,399 $696,000
Q3 2022

Nov 14, 2022

BUY
$60.57 - $79.51 $908 - $1,192
15 Added 1.0%
1,519 $99,000
Q2 2022

Aug 12, 2022

SELL
$58.04 - $100.2 $36,855 - $63,627
-635 Reduced 29.69%
1,504 $108,000
Q1 2022

May 16, 2022

SELL
$55.89 - $101.89 $7,321 - $13,347
-131 Reduced 5.77%
2,139 $210,000
Q4 2021

Feb 14, 2022

BUY
$72.34 - $95.09 $21,267 - $27,956
294 Added 14.88%
2,270 $192,000
Q3 2021

Nov 15, 2021

SELL
$78.35 - $105.02 $7,991 - $10,712
-102 Reduced 4.91%
1,976 $158,000
Q2 2021

Aug 10, 2021

SELL
$97.2 - $137.59 $39,074 - $55,311
-402 Reduced 16.21%
2,078 $202,000
Q1 2021

May 17, 2021

BUY
$108.54 - $125.2 $3,907 - $4,507
36 Added 1.47%
2,480 $290,000
Q4 2020

Feb 12, 2021

SELL
$110.06 - $133.7 $47,876 - $58,159
-435 Reduced 15.11%
2,444 $272,000
Q3 2020

Nov 13, 2020

SELL
$99.78 - $124.21 $40,710 - $50,677
-408 Reduced 12.41%
2,879 $342,000
Q2 2020

Aug 05, 2020

SELL
$60.13 - $125.71 $23,811 - $49,781
-396 Reduced 10.75%
3,287 $372,000
Q1 2020

May 14, 2020

SELL
$66.76 - $93.49 $36,250 - $50,765
-543 Reduced 12.85%
3,683 $246,000
Q4 2019

Feb 13, 2020

BUY
$84.28 - $118.5 $137,039 - $192,681
1,626 Added 62.54%
4,226 $385,000
Q3 2019

Nov 12, 2019

SELL
$84.4 - $106.53 $12,153 - $15,340
-144 Reduced 5.25%
2,600 $224,000
Q2 2019

Aug 13, 2019

BUY
$91.13 - $142.5 $250,060 - $391,020
2,744 New
2,744 $288,000
Q1 2019

May 14, 2019

SELL
$103.48 - $143.84 $279,396 - $388,368
-2,700 Closed
0 $0
Q4 2018

Feb 05, 2019

BUY
$94.77 - $215.54 $106,331 - $241,835
1,122 Added 71.1%
2,700 $304,000
Q3 2018

Nov 14, 2018

SELL
$207.3 - $300.31 $232,383 - $336,647
-1,121 Reduced 41.53%
1,578 $338,000
Q2 2018

Aug 10, 2018

SELL
$101.55 - $313.9 $703,741 - $2.18 Million
-6,930 Reduced 71.97%
2,699 $755,000
Q1 2018

May 14, 2018

BUY
$93.35 - $149.04 $489,807 - $782,012
5,247 Added 119.74%
9,629 $1.13 Million
Q4 2017

Feb 14, 2018

BUY
$39.35 - $97.37 $172,431 - $426,675
4,382
4,382 $402,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $3.63B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.